Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Eisai, Biogen And Alzheimer's: Never Say Die, Lecanemab To The Rescue
11:56am, Friday, 30'th Sep 2022
Eisai and Biogen get another chance. Still not a cure, but a big step forward even though it's still just a glimmer of hope for Alzheimer's sufferers. The big news is that lecanemab produced a measura
Biogen and Alzheimer's drug development companies surge on positive clinical data
11:21am, Friday, 30'th Sep 2022
Alzheimer's drug development companies have been handed a boost in share prices this week following data for the pioneering treatment lecanemab. Positive late-stage clinical data announced by Biogen I
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab)
11:00am, Friday, 30'th Sep 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for BIIB
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
10:48am, Friday, 30'th Sep 2022
The major indexes fell, with the S&P 500 breaking below bear market lows. Biogen soared on an Alzheimer's drug while Nike dived.
9 Stocks Turned $10,000 Into $129,224 In 9 Months
08:00am, Friday, 30'th Sep 2022
It's a tough S&P 500 stock market to make money on. But some investors are still finding a way to do it.
Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates
04:12pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.
LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data
01:39pm, Thursday, 29'th Sep 2022 Zacks Investment Research
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Stock Market News for Sep 29, 2022
01:10pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Wall Street closed sharply higher on Wednesday rebounding from a six-day losing streak.
Will Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?
12:49pm, Thursday, 29'th Sep 2022 MarketWatch
Some analysts are tempering their expectations of lecanemab until they get a better idea if Medicare will pay for the drug.
Teamwork Pays: Biogen, Eisai Announce Positive Results For Alzheimer's Drug
12:09pm, Thursday, 29'th Sep 2022
Biogen and Eisai announce positive clinical results for lecanemab, a novel treatment for Alzheimer's disease. Lecanemab continues the collaboration between the companies, after the controversial appro
Biogen's Alzheimer's drug could generate ‘$8 billion in peak sales': Analyst
10:40am, Thursday, 29'th Sep 2022
Mizuho Americas Senior Biotech Analyst Salim Syed joins Yahoo Finance Live anchors Julie Hyman and Brad Smith to discuss encouraging Phase 3 data from Biogen's Alzheimer's treatment lecanemab, how man
Is Biogen a Smart Biotech Stock to Buy Right Now?
09:13am, Thursday, 29'th Sep 2022 The Motley Fool
New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
09:09am, Thursday, 29'th Sep 2022 Benzinga
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria
Netflix, Biogen And Other Big Gainers From Wednesday
07:45am, Thursday, 29'th Sep 2022 Benzinga
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Acumen Pharmaceuticals, Inc. (NAS
Is Biogen a Smart Biotech Stock to Buy Right Now?
05:13am, Thursday, 29'th Sep 2022
New clinical trial results are great, but this company's Alzheimer's disease program has deeply disappointed investors in the past.
